Cross-border pharmacy services in the EU: How generic drugs move across borders

Imagine you’re on vacation in Belgium and your blood pressure medication runs out. Back home in Germany, your doctor e-signed a prescription that’s already waiting for you at the local pharmacy across the border. No paperwork. No delays. Just walk in, show your ID, and pick up your pills. This isn’t science fiction-it’s real in the EU today, thanks to the ePrescription system. But here’s the catch: not everyone can use it, and not every country plays by the same rules.

How cross-border pharmacy services actually work

The EU’s cross-border pharmacy system is built on two digital tools: ePrescription and Patient Summaries. Together, they let you get your generic drugs in another EU country using your home country’s prescription. The system runs on the eHealth Digital Service Infrastructure (a secure digital network connecting national health systems across the EU), branded as MyHealth@EU. It’s active in all 27 EU countries plus Iceland, Norway, and Liechtenstein.

Here’s how it works step by step:

1. Your doctor in France issues an electronic prescription linked to your national health ID.
2. You travel to Spain and visit a participating pharmacy.
3. The pharmacist logs into the MyHealth@EU portal using your European Health Insurance Card (EHIC) number.
4. The system pulls up your ePrescription and your Patient Summary-showing allergies, current meds, and past treatments-in Spanish.
5. The pharmacist dispenses the generic version of your drug, and the transaction is recorded back in France.

This isn’t just convenient. It saves lives. In border regions like the Netherlands-Germany border, 78% of patients report successfully filling prescriptions abroad, compared to just 42% elsewhere in the EU. The system cuts down on medication errors by 22% and improves adherence to chronic disease treatments by 17%.

Why generic drugs are the backbone of this system

Generic drugs make cross-border mobility possible because they’re identical in active ingredients, dosage, and safety to brand-name versions-but cheaper and more widely available. A patient in Sweden might need a generic version of metformin for diabetes. In Germany, that same drug is sold under a different brand name, but the active ingredient is the same. The EU’s strict bioequivalence rules ensure that a generic pill bought in Poland works the same as one bought in Finland.

But here’s the problem: not every country stocks every generic. A drug approved in Italy might not be available in Romania. Pharmacists can’t just substitute any generic-they must match the exact formulation listed in the ePrescription. That’s why Patient Summaries are so critical. They show not just the drug name, but the manufacturer and batch number. If the pharmacy in Portugal doesn’t carry the exact version, they can’t legally dispense it.

The regulatory patchwork: 8 countries lead, 19 lag

The EU has a single law for cross-border healthcare-Directive 2011/24/EU-but implementation is a mess. Only 8 EU countries have clear rules for how pharmacists should handle e-prescriptions from abroad. Germany, France, Austria, the Netherlands, Belgium, Denmark, Luxembourg, and Estonia have fully integrated systems. In these places, pharmacists get training, clear guidelines, and digital tools to verify foreign prescriptions.

In the other 19? It’s a gamble. Pharmacists in Greece, Bulgaria, or Croatia may not even know how to access the MyHealth@EU portal. Some don’t have the software. Others lack training. Patients report being turned away because the pharmacist “didn’t recognize the foreign prescription format.”

And it’s not just about software. Regulations vary wildly. In Ireland, prescriptions from UK telehealth services are invalid-even if the doctor is licensed and the prescription is real. Why? Because the UK left the EU’s digital health network. The same goes for Switzerland and Norway: not part of the EU, so their ePrescriptions don’t connect. Even within the EU, some countries require patients to manually authorize data sharing for each trip. Others do it automatically. It’s confusing. And dangerous.

The new rules changing everything in 2025

This year, the EU rolled out major updates. The Critical Medicines Act (a regulation requiring manufacturers to report supply and demand data across borders) forces drugmakers to track shortages in real time. If a generic drug runs out in Spain, the system flags it. Pharmacies in neighboring countries can then redirect patients to stock that’s available elsewhere.

Italy now uses GS1 DataMatrix codes (scannable 2D barcodes replacing paper stickers on prescriptions). These codes hold more data than old paper labels-dosage, batch, expiry, even the prescriber’s license number. It’s harder to fake. Pharmacists scan the code, and the system auto-verifies everything.

Meanwhile, the European Shortages Medicines Platform (a centralized database tracking drug availability across all EU states) went live in January 2025. It’s already helped reroute 12,000 prescriptions in the first three months, mostly for generics used in heart disease and diabetes.

What goes wrong-and who gets left behind

The biggest issue? Awareness. Only 38% of EU citizens know they can get their meds abroad. In non-border areas, that number drops below 20%. Most people think they need to go back home to refill prescriptions. They don’t realize they can walk into a pharmacy in Croatia and get their German-prescribed insulin.

Then there’s language. A patient from Poland with a prescription for a generic anticoagulant might not understand the label in Czech. Patient Summaries help-they translate your medical history-but not all countries use them properly. Some only show the summary if the patient manually requests it. Others don’t translate at all.

And let’s not forget the elderly. Many don’t have smartphones or digital IDs. They rely on paper prescriptions. If they travel, they’re stuck. The system doesn’t yet support paper-to-digital conversion across borders. A 72-year-old in Hungary with arthritis might have to fly home just to refill a generic painkiller.

What’s next? The road to 2030

By 2027, MyHealth@EU will expand beyond prescriptions. You’ll be able to access lab results, imaging scans, and hospital discharge summaries while abroad. Imagine showing up at a clinic in Portugal with a heart condition, and the doctor instantly sees your echocardiogram from your home hospital in Sweden.

The market is growing fast. The EU cross-border pharmacy sector is expected to grow 14.3% per year until 2030. More seniors are traveling. More people have chronic diseases. More generics are being approved. But growth won’t mean equity unless the EU fixes the fragmentation.

Right now, the system works best where it’s been tested: in border towns, in countries with strong digital health systems, and for patients who know their rights. For everyone else? It’s still a gamble.

Until every pharmacy in every country can reliably access your prescription and understand your medical history-no matter where you’re from-the promise of cross-border mobility remains incomplete.